- Conditions
- Inflammatory Bowel Disease (IBD), Crohn&Amp;#39;s Disease (CD), Ulcerative Colitis (UC)
- Interventions
- Patient switched from IV vedolizumab to subcutaneous vedolizumab as part of normal patient care
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 4:18 AM EDT